A Study of LAM-002A for the Prevention of Progression of COVID-19

Summary

This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.

Timeline

Start

2020-07-15

Primary completion

2021-03-24

Completion

2021-04-19

Outcome

Missed primary endpoint

registry analysis (superiority test); LAM-002A vs Placebo; p = 0.35; Mean Difference (Final Values) -0.47 (95% CI -1.47 to 0.53) NCT04446377 ↗

Publications

• Kumar P, Mathayan M, Smieszek SP, Przychodzen BP, Koprivica V, Birznieks G, Polymeropoulos MH, Prabhakar BS. Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. Virology. 2022 Jul;572:64-71. doi: 10.1016/j.virol.2022.05.004. Epub 2022 May 16.

Drugs

Indications